Reference standard is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-22. Numbers and descriptions here follow the published literature rather than marketing material.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Modern birds communicate by visual and auditory signals, and the wide diversity of visual display structures among fossil dinosaur groups, such as horns, frills, crests, sails, and feathers, suggests that visual communication has always been important in dinosaur biology. Reconstruction of the plumage color of Anchiornis suggest the importance of color in visual communication in non-avian dinosaurs. A 2009 review indicated that non-avians used visual displays and possibly non-vocal sounds, such as hissing, jaw-grinding or -clapping, splashing, and wing-beating (possible in winged maniraptoran dinosaurs). Fossilized larynxes or voice boxes have been identified in two dinosaurs; the ankylosaurid Pinacosaurus and the neornithischian Pulaosaurus, the structures of which suggest that dinosaurs were capable of complex bird-like vocalizations. A 2016 study concludes that some dinosaurs may have produced closed-mouth vocalizations, such as cooing, hooting, and booming. These occur in both reptiles and birds and involve inflating the esophagus or tracheal pouches. Such vocalizations evolved independently in extant archosaurs numerous times, following increases in body size. The crests of some hadrosaurids and the nasal chambers of ankylosaurids may have been resonators. Birds have evolved a novel organ for vocalization, the syrinx, the earliest remains of which were found in a specimen of the duck-like Vegavis iaai dated 69 –66 million years ago. The syrinx may have supplemented and then replaced the larynx as a vocal organ during bird evolution.
This differential equation is the classic equation of motion for charged particles. Together with the particle's initial conditions, it completely determines the particle's motion in space and time in terms of m/Q. Thus mass spectrometers could be thought of as "mass-to-charge spectrometers". When presenting data, it is common to use the (officially) dimensionless m/z, where z is the number of elementary charges (e) on the ion (z=Q/e). This quantity, although it is informally called the mass-to-charge ratio, more accurately speaking represents the ratio of the mass number and the charge number, z.
By 1818, the United States Navy had outlined that each sailor was to be given 14 ounces (400 g) of bread per day as part of their daily ration while serving onboard in the form of hardtack. The procurement of these stores was the responsibility of the ship's Purser, and was not strictly outlined by the Board of Navy Commissioners. During the American Civil War (1861–1865), three-by-three-inch (7.6 by 7.6 cm) hardtack was shipped from Union and Confederate storehouses. Civil War soldiers generally found their rations to be unappealing; hardtack's ability to host worms earned it the "worm castles" nickname, and soldiers joked about the poor quality of the hardtack in the satirical song "Hard Tack Come Again No More". The song was sung to the tune of the Stephen Foster song "Hard Times Come Again No More", and featured lyrics describing the hardtack rations as being 'old and very wormy' and causing many 'stomachs sore'. John Billings, a soldier in the 10th Massachusetts Battery, outlines many details on how hardtack was utilized during the war in his book Hard Tack and Coffee.
== Medical uses == Tazarotene is most commonly used topically to treat acne vulgaris, psoriasis, and photoaging. Like other topical retinoids, such as tretinoin and adapalene, tazarotene can be used in a regimen with benzoyl peroxide and/or an oral antibiotic, such as clindamycin or dapsone, for the treatment of acne. This results in increased efficacy compared to tazarotene monotherapy. Combination therapy utilizing tazarotene alongside a mid- to high-potency corticosteroid is more effective in treating psoriasis compared to monotherapy of either drug. Tazarotene can also be used for the treatment of photodamaged skin. It can reduce the histological and clinical signs of photodamaged skin, such as fine lines, wrinkles, hyperpigmentation, and lentigo. The therapy is more effective when used with the daily application of sunscreen.
Sources: en.wikipedia.org
== Venom == Bites from H. hypnale, although previously thought to be innocuous, are now known to cause serious complications such as coagulopathy and acute renal failure (ARF). If not treated within a few hours, bites can potentially be fatal for human beings. While not initially included in the list of highly venomous snakes in Sri Lanka, it is now considered highly venomous, and one of the medically important venomous snakes in Sri Lanka and on the south western coast of India. As of November 2016, an antivenom is currently being developed by the Costa Rican Clodomiro Picado Institute, and clinical trial phase in Sri Lanka.
== History == In 2018, three unrelated children who had similar symptoms of developmental delays, skeletal abnormalities, and mild dysmorphic facial features. The first patient had an autism diagnosis and mild skeletal abnormalities but was otherwise normal. The second patient had poor growth in infancy, difficulty walking, tremors, difficulty speaking, and needed to be homeschooled due to academic difficulties. The third patient had microcephaly, poor growth, and was slow to learn how to walk but was able to attend mainstream school. All three of these patients had a variety of dysmorphic facial features that none of the patients shared except for a prominent nose, wide mouth, and thin upper lip. They were identified as having a de novo mutation on their QRICH1 gene. In 2019, 2 unrelated children were identified as having VERBAS and were found to have subtle chondrodysplasia. In 2021, Fohrenbach et al. described 4 unrelated patients with VERBAS. One patient, a three-year-old, developed nephroblastoma and died from complications, suggesting that increased cancer risk may be a part of the syndrome. In 2023, a 17-year-old girl was suffering from seizures and leukodystrophy. The girl had a history of minor developmental delays and was thought to have a perinatal brain injury resulting in mild right-side paresis. Her mother shared similar dysmorphic facial features, short stature, and distractable nature, causing them to be referred to a genecist. It was discovered that they both carried a novel QRICH1-related mutation and were diagnosed with VERBRAS.
Although access to judicial review is restricted for ordinary questions of law, the Court of Justice has gradually developed a more open approach to standing for human rights. Human rights have also become essential in the proper interpretation and construction of all EU law. If there are two or more plausible interpretations of a rule, the one which is most consistent with human rights should be chosen. The Treaty of Lisbon 2007 made rights underpin the Court of Justice's competence, and required the EU's accession to the European Convention on Human Rights, overseen by the external Strasbourg Court. Initially, reflecting its primitive economic nature, the treaties made no reference to rights. However, in 1969 particularly after concern from Germany, the Court of Justice declared in Stauder v City of Ulm that 'fundamental human rights' were 'enshrined in the general principles of Community law'. This meant that Mr Stauder, who received subsidised butter under an EU welfare scheme only by showing a coupon with his name and address, was entitled to claim that this violated his dignity: he was entitled not to have to go through the humiliation of proving his identity to get food. While those 'general principles' were not written down in EU law, and simply declared to exist by the court, it accords with a majority philosophical view that 'black letter' rules, or positive law, necessarily exist for reasons that the society which made them wants: these give rise to principles, which inform the law's purpose.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.